88 related articles for article (PubMed ID: 17294577)
1. [Experiences of the DREAM trial].
Fövényi J
Orv Hetil; 2006 Dec; 147(52):2523-6. PubMed ID: 17294577
[TBL] [Abstract][Full Text] [Related]
2. Diabetes prevention: still no effective drugs.
Prescrire Int; 2007 Dec; 16(92):258. PubMed ID: 18095391
[TBL] [Abstract][Full Text] [Related]
3. [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].
Scheen AJ
Rev Med Liege; 2006 Oct; 61(10):728-32. PubMed ID: 17209507
[TBL] [Abstract][Full Text] [Related]
4. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.
Hanley AJ; Zinman B; Sheridan P; Yusuf S; Gerstein HC;
Diabetes Care; 2010 Mar; 33(3):608-13. PubMed ID: 20009095
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
; Gerstein HC; Yusuf S; Bosch J; Pogue J; Sheridan P; Dinccag N; Hanefeld M; Hoogwerf B; Laakso M; Mohan V; Shaw J; Zinman B; Holman RR
Lancet; 2006 Sep; 368(9541):1096-105. PubMed ID: 16997664
[TBL] [Abstract][Full Text] [Related]
6. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
; Dagenais GR; Gerstein HC; Holman R; Budaj A; Escalante A; Hedner T; Keltai M; Lonn E; McFarlane S; McQueen M; Teo K; Sheridan P; Bosch J; Pogue J; Yusuf S
Diabetes Care; 2008 May; 31(5):1007-14. PubMed ID: 18268075
[TBL] [Abstract][Full Text] [Related]
7. [Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].
Standl E; Nitschmann S
Internist (Berl); 2007 Oct; 48(10):1173-6. PubMed ID: 17846732
[No Abstract] [Full Text] [Related]
8. Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.
McFarlane SI; Provilus A; Shin JJ
J Cardiometab Syndr; 2007; 2(2):149-50. PubMed ID: 17684471
[No Abstract] [Full Text] [Related]
9. [The DREAM of diabetes prevention].
Ruiz J
Rev Med Suisse; 2007 Jan; 3(94):132, 134-6. PubMed ID: 17354538
[TBL] [Abstract][Full Text] [Related]
10. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Scheen AJ
Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
[TBL] [Abstract][Full Text] [Related]
11. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Lonn EM; Gerstein HC; Sheridan P; Smith S; Diaz R; Mohan V; Bosch J; Yusuf S; Dagenais GR;
J Am Coll Cardiol; 2009 Jun; 53(22):2028-35. PubMed ID: 19477351
[TBL] [Abstract][Full Text] [Related]
12. Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
Boyko EJ; Gerstein HC; Mohan V; Yusuf S; Sheridan P; Anand S; Shaw JE;
Diabet Med; 2010 Nov; 27(11):1226-32. PubMed ID: 20950379
[TBL] [Abstract][Full Text] [Related]
13. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.
Gerstein HC; Yusuf S; Holman R; Bosch J; Pogue J;
Diabetologia; 2004 Sep; 47(9):1519-27. PubMed ID: 15322749
[TBL] [Abstract][Full Text] [Related]
14. [The effectiveness in type 2 diabetes prevention: a forced landing to reality].
Costa B
Med Clin (Barc); 2008 Mar; 130(8):295-7. PubMed ID: 18358121
[No Abstract] [Full Text] [Related]
15. Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.
Nathan DM; Berkwits M
Ann Intern Med; 2007 Mar; 146(6):461-3. PubMed ID: 17371892
[No Abstract] [Full Text] [Related]
16. [Three studies in type 2 diabetes: DREAM the wash-out results].
Roussel R
Ann Endocrinol (Paris); 2007 Jun; 68 Suppl 1():36-8. PubMed ID: 17961660
[No Abstract] [Full Text] [Related]
17. Effect of ramipril on the incidence of diabetes.
; Bosch J; Yusuf S; Gerstein HC; Pogue J; Sheridan P; Dagenais G; Diaz R; Avezum A; Lanas F; Probstfield J; Fodor G; Holman RR
N Engl J Med; 2006 Oct; 355(15):1551-62. PubMed ID: 16980380
[TBL] [Abstract][Full Text] [Related]
18. Incidence of diabetes following ramipril or rosiglitazone withdrawal.
DREAM Trial Investigators
Diabetes Care; 2011 Jun; 34(6):1265-9. PubMed ID: 21515846
[TBL] [Abstract][Full Text] [Related]
19. Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.
Rahman S; Ismail AA; Ismail SB; Naing NN; Abdul Rahman AR
Eur J Clin Pharmacol; 2007 Aug; 63(8):733-41. PubMed ID: 17565489
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.
; Gerstein HC; Mohan V; Avezum A; Bergenstal RM; Chiasson JL; Garrido M; MacKinnon I; Rao PV; Zinman B; Jung H; Joldersma L; Bosch J; Yusuf S
Diabetologia; 2011 Mar; 54(3):487-95. PubMed ID: 21116607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
